Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Published . Updated .
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Directly affected
- No company is named in this report.
Indirectly affected
- SUPX SUPERX AI TECHNOLOGY LTD
GA selected SUPX as a RELATED security because its canonical security name directly matches this event's themes: technology, ai. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ABAT AMERICAN BATTERY TECHNOLOGY
GA selected ABAT as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACM AECOM TECHNOLOGY CORP
GA selected ACM as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- AOSL ALPHA & OMEGA SEMICONDUCTOR LT SHS
GA selected AOSL as a RELATED security because its canonical security name directly matches this event's themes: semiconductor. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Source: TechCrunch
SuperX AI Technology (SUPX) since this story, compared with the market
Since the first closing price after “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials,” SuperX AI Technology (SUPX) is -2.82%. The S&P 500 fund (SPY) is -0.09% over the same days, a -2.73% difference versus the market.
Who reported a SuperX AI Technology (SUPX) trade near this story
- Donald J Trump buy Aecom (ACM) ($1,001 - $15,000). That is 26 days before publication, inside 30 days. The filing is listed beside the story “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials.”
- Donald J Trump sell Aecom (ACM) ($1,001 - $15,000). That is 30 days before publication, inside 30 days. The filing is listed beside the story “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around SuperX AI Technology (SUPX)
Companies mentioned with this story
- SUPX SuperX AI Technology
SuperX AI Technology (SUPX) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials.” Reason on file: GA selected SUPX as a RELATED security because its canonical security name directly matches this event's themes: technology, ai. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ABAT American Battery Technology
For “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials,” American Battery Technology (ABAT) is linked, with no stored direction, medium confidence. Reason on file: GA selected ABAT as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACM Aecom
In “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials,” Aecom (ACM) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACM as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- AOSL Alpha & Omega Semiconductor
Alpha & Omega Semiconductor (AOSL) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials.” Reason on file: GA selected AOSL as a RELATED security because its canonical security name directly matches this event's themes: semiconductor. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
SuperX AI Technology (SUPX)
On 23 Sep 2026, “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials” is the story that connects SuperX AI Technology (SUPX) to this story.
For SuperX AI Technology (SUPX), the reason on file says GA selected SUPX as a RELATED security because its canonical security name directly matches this event's themes: technology, ai. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
American Battery Technology (ABAT) is here too. Its reason reads: GA selected ABAT as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for SuperX AI Technology (SUPX), and the dates in the story
ABAT traded between 1.42 and 2.42 across 20 sessions. The latest close on file is 1.44. ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. SUPX traded between 6.15 and 7.09 across 10 sessions. The latest close on file is 6.72.
How strong the case is around SuperX AI Technology (SUPX)
46 out of 100
“Enveda secures $311M to bring more nature-derived AI drugs into clinical trials” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.